GB002, a Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the SU5416 Hypoxia Rat Model of PAH

GB002, a Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in the SU5416 Hypoxia Rat Model of PAH

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study